

Kişisel Bilgiler

E-posta: cagri.yildirim@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/cagri.yildirim>

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Acute heart failure following pazopanib treatment: a literature review featuring two case reports**
KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.
Anti-Cancer Drugs, cilt.35, sa.3, ss.302-304, 2024 (SCI-Expanded)
- II. **The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study**
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., Şakalar T., Celayir Ö. M., KAYIKÇIOĞLU E., Aslan F., et al.
International Journal of Clinical Oncology, cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded)
- III. **Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study**
YILDIRIM H. Ç., Kapar C., KÖKSAL B., Seyyar M., Sancı P. C., Guliyev M., Perkin P., Buyukkor M., YASLIKAYA Ş., Majidova N., et al.
Journal of Chemotherapy, 2024 (SCI-Expanded)
- IV. **Sirolimus experience in adult patients with vascular malformations**
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., Chalabiyev E., TÜRKER F. A., DİZDAR Ö., YALÇIN Ş., et al.
Vascular, 2024 (SCI-Expanded)
- V. **A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology**
YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.
Irish Journal of Medical Science, cilt.192, sa.6, ss.2631-2634, 2023 (SCI-Expanded)
- VI. **A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer**
YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., YALÇIN Ş.
Anti-cancer drugs, cilt.34, sa.10, ss.1190-1192, 2023 (SCI-Expanded)
- VII. **PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study**
Avcı O., İriağaç Y., Çavdar E., Karaboyun K., Araz M., Şakalar T., Değerli E., Özdemir Ö., İnal A., Ocak B., et al.
Journal of Geriatric Oncology, cilt.14, sa.8, 2023 (SCI-Expanded)
- VIII. **Advances in the Early Detection of Hepatobiliary Cancers**
YILDIRIM H. Ç., KAVGACI G., Chalabiyev E., DİZDAR Ö.
Cancers, cilt.15, sa.15, 2023 (SCI-Expanded)
- IX. **The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors**
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., YILDIRIM H. Ç., Chalabiyev E., Cebroyilov C., YILDIRIM T., et al.

Anti-Cancer Drugs, cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded)

- X. **SMART syndrome: a case report**
Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., Oguz K. K., DİZDAR Ö.
ACTA NEUROLOGICA BELGICA, cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded)
- XI. **Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort**
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., Chalabiyev E., KUŞ F., YALÇIN Ş., AKSOY S.
Medicine (United States), cilt.102, sa.18, 2023 (SCI-Expanded)
- XII. **The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma**
GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., Kaygusuz Y., ÇAYIRÖZ K., ÜÇDAL M. T., Yesil F., et al.
European Archives of Oto-Rhino-Laryngology, cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded)
- XIII. **KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer**
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., ŞAHİN Y., Ileri S., Karaca E., KERTMEN N., et al.
Biomarkers in Medicine, cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded)
- XIV. **Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy**
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., YÜCE D., ARIK Z., KILIÇKAP S., AKSOY S., et al.
INTERNATIONAL JOURNAL OF CANCER, cilt.152, ss.679-685, 2023 (SCI-Expanded)
- XV. **Knowledge and Protective Behaviors of Teachers on Skin Cancer: A Cross-Sectional Survey Study from Turkey**
Kus C., Kus M. M., Keten H. S., Ucer H., Guvenc N., KUŞ F., YILDIRIM H. Ç., Akbayram H. T.
Children, cilt.10, sa.2, 2023 (SCI-Expanded)
- XVI. **Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study**
GÜRSOY P., TATLI A. M., Erdem D., GÖKER E., Celik E., Demirci N. S., Sakin A., Atci M. M., Bayram E., AKIN TELLİ T., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.149, sa.2, ss.865-875, 2023 (SCI-Expanded)
- XVII. **Emerging treatment strategies in hepatobiliary cancer**
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., AKYILDIZ A., AKTAŞ B. Y., YALÇIN Ş., DİZDAR Ö.
Expert Review of Anticancer Therapy, cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded)
- XVIII. **Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment**
Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., AKSOY S.
Expert Review of Anticancer Therapy, cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded)
- XIX. **Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study**
YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., Celebi A., DURSUN B., Acar O., KAHRAMAN S., et al.
BREAST, cilt.66, ss.85-88, 2022 (SCI-Expanded)
- XX. **Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKSOY S., ERMAN M., Kilickap S., YALÇIN Ş.
JOURNAL OF CLINICAL MEDICINE, cilt.11, sa.17, 2022 (SCI-Expanded)
- XXI. **The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy**

- GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., AKTEPE O. H., ERMAN M., KILIÇKAP S., AKSOY S., et al.
JOURNAL OF CLINICAL MEDICINE, cilt.11, sa.15, 2022 (SCI-Expanded)
- XXII. **Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study**
Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., Tunc S., Ozyurt N., Ozdemir F., Sendur M. A. N., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.4, 2022 (SCI-Expanded)
- XXIII. **HER2-low breast cancer could be associated with an increased risk of brain metastasis**
GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., KERTMEN N., DİZDAR Ö., ÜNER A., AKSOY S.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded)
- XXIV. **Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)**
Erol C., Sakin A., Başoglu T., Özden E., ÇABUK D., Doğan M., Öksüzöğlü B., YILDIRIM H. Ç., Öner İ., Karakurt Eryilmaz M., et al.
Turkish Journal of Medical Sciences, cilt.52, sa.4, ss.1022-1032, 2022 (SCI-Expanded)
- XXV. **The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study**
GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., KERTMEN N., DİZDAR Ö., AKSOY S.
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded)
- XXVI. **A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer**
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, cilt.168, 2021 (SCI-Expanded)
- XXVII. **The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy**
AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., YÜCE D., DİZDAR Ö., ERMAN M.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded)
- XXVIII. **Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., ÜÇGÜL E., AKSUN M. S., GÜRBÜZ S. Ç., AKTEPE O. H., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)
- XXIX. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.
SUPPORTIVE CARE IN CANCER, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded)
- XXX. **Impact of coronaphobia on treatment and follow-up compliance of cancer patients**
Akagunduz B., Ozer M., Karacin C., Atci M. M., YILDIRIM H. Ç., Unver E.
FUTURE ONCOLOGY, cilt.17, ss.2621-2629, 2021 (SCI-Expanded)
- XXXI. **Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report**
GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.27, sa.5, ss.1281-1283, 2021 (SCI-Expanded)
- XXXII. **Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group**
Akagunduz B., AKIN TELLİ T., YILDIRIM H. Ç., SEZGİN GÖKSU S., DEMİR N., Hafizoglu E., Ozer M., Cevik G. T., Sakin A., Aydin S. G., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.31, sa.2, ss.92-98, 2021 (SCI-Expanded)
- XXXIII. **Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19**

Diğer Dergilerde Yayınlanan Makaleler

- I. **Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab**
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., AKSOY S., ERMAN M., YALÇIN Ş., Kilickap S.
Journal of Immunotherapy and Precision Oncology, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
- II. **Leptomeningeal metastasis in primary uterine cervical cancer: a rare case and review of the literature**
KAHVECİOĞLU A., Sari S. Y., YILDIRIM H. Ç., ARIK Z., GÜLTEKİN M., YILDIZ F.
Corrosion Science and Technology, cilt.19, sa.3, ss.184-189, 2023 (ESCI)
- III. **Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer**
YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., AKYILDIZ A., YILMAZ F., YAŞAR S., Evlendi Y., et al.
Journal of Oncological Science, cilt.9, sa.1, ss.33-37, 2023 (Scopus)
- IV. **Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review**
YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., AKIN S., YALÇIN Ş., BARIŞTA İ.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, cilt.15, sa.4, ss.307-310, 2022 (ESCI)
- V. **Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKTAŞ B. Y., GÜNER G., DİZDAR Ö., AKSOY S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.6, sa.1, ss.59-63, 2022 (ESCI)
- VI. **Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy**
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., KUŞ F., AKYILDIZ A., GÜRBÜZ S. Ç., Sayin H., et al.
Journal of Oncological Science, cilt.8, sa.3, ss.143-147, 2022 (Scopus)
- VII. **Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma**
AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., Ardic F. S., Yeter H. H., YÜCE D., ERMAN M.
TURKISH JOURNAL OF UROLOGY, cilt.47, sa.2, ss.113-119, 2021 (ESCI)
- VIII. **Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery**
Akagunduz B., AKIN TELLİ T., SEZGİN GÖKSU S., YILDIRIM H. Ç., Ozer M., Aydın S. G., Ozyurt N., Karacin C., PAYDAŞ S., Dogan M.
CUREUS, cilt.13, sa.2, 2021 (ESCI)

Metrikler

Yayın: 41

Atıf (WoS): 1

Atıf (Scopus): 79

H-İndeks (WoS): 1

H-İndeks (Scopus): 5